AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress

Press Releases   •   Sep 13, 2018 14:22 BST

– Across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo1

– At week 32, patients who switched from placebo to upadacitinib 30 mg at week 16 showed greater improvements in skin lesions and itch compared to those remaining on placebo1

– Results from an additional analysis of a subset of patients receiving upadacitinib 30 mg reported greater improvements in itch and sleep disturbance compared to those receiving placebo at week 162

Maidenhead, UK, 13th September 2018 – AbbVie, a research-based global biopharmaceutical company, today announced new results from the ongoing Phase 2b study including longer-term (32-week) efficacy and safety data and patient-reported outcomes data evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe atopic dermatitis.1,2 Results from a pre-specified, interim analysis from the Phase 2b dose-ranging study showed that treatment with upadacitinib 7.5 mg, 15 mg or 30 mg resulted in greater improvements in itch and skin lesions, with statistically significant differences observed versus placebo at week 32 (n=167).1 Additionally, results from a further analysis of a subset of patients (n=44) showed that upadacitinib improved patient-reported itch and impact on sleep due to atopic dermatitis in patients receiving upadacitinib (30 mg, once-daily) compared to placebo at week 16.2 Data from these two analyses will be presented today at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

“Results from this study increase our understanding of upadacitinib’s potential to be an important treatment option for patients living with atopic dermatitis,” said Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie. “At AbbVie, we continuously strive to discover and develop innovative medicines for patients who are in need of more treatment options that advance standards of care and improve quality of life. Data from the mid-stage clinical study support the recent advancement of upadacitinib into Phase 3 clinical studies and underscore our commitment to patients with atopic dermatitis.”

Atopic dermatitis is a common chronic, relapsing, inflammatory skin disease with associated comorbidities.4 One-third of atopic dermatitis patients have moderate to severe disease, which manifests as a debilitating, itchy rash with significant physical, psychological and economic burden.4,5 There is a large unmet need for therapies that are effective to manage the signs and symptoms of moderate to severe atopic dermatitis.

“The symptoms associated with atopic dermatitis can have a profound impact on patients’ quality of life, causing serious discomfort and pain, and impacting their ability to sleep,” said Jonathan Silverberg, M.D., Ph.D., M.P.H., Associate Professor of Dermatology, Medical Social Sciences and Preventive Medicine, Northwestern University Feinberg School of Medicine and lead study investigator. “The patient-reported outcome results presented at EADV are encouraging, and provide further insight into the improvement provided by upadacitinib in patients with moderate to severe atopic dermatitis.”

Longer-Term Results at Week 321

These results are from an interim analysis at week 32 of an ongoing Phase 2b study entitled, “Efficacy and Safety of Upadacitinib Treatment Over 32 Weeks for Patients with Atopic Dermatitis from a Phase 2b, Randomized, Placebo-Controlled Trial” (P0236). 1 At week 16, patients in each upadacitinib group were re-randomized in a 1:1 ratio to continue on the Period 1 dose (7.5[n=16] /15[n=18] /30[n=19] mg once-daily) or to placebo (withdrawal) (n=15/19/19 subjects in UPA 7.5/15/30 mg period 1 dose), while the Period 1 placebo group was re-randomized to receive upadacitinib 30 mg once-daily (n=10) or placebo (n=10).1 Four weeks following re-randomization (week 20), blinded rescue therapy with upadacitinib 30 mg once-daily was provided after the first instance of a less than EASI 50 response.1

Results showed that patients treated with upadacitinib across all dose groups (7.5/15/30 mg once-daily) achieved significant improvement in extent and severity of atopic dermatitis, as measured by the mean percent improvement from baseline in the Eczema Area and Severity Index (EASI) score.1 For patients receiving upadacitinib, the mean percent improvement from baseline in the EASI score was 48/44/69 percent for the 7.5/15/30 mg doses, respectively, compared to 34 percent for patients receiving placebo.1 Among patients receiving placebo in Period 1 and re-randomized to receive the upadacitinib 30 mg dose in Period 2, the mean percent improvement from baseline in the EASI score was 97 percent at week 32.1

Additionally, significant improvement in pruritus (itch) from baseline was observed across all upadacitinib treatment groups at week 32.1 Patients re-randomized to upadacitinib achieved a 53/44/61 percent improvement in itch across the 7.5/15/30 mg doses, respectively, compared to 6 percent worsening in itch for patients receiving placebo, as measured by the pruritus numerical rating scale (NRS).1

Efficacy Results at Week 321
Period 1 Dose PBO UPA 7.5 mg UPA 15 mg UPA 30 mg
Period 2 Dose PBO (n=10) UPA 30 mg (n=10) PBO (n=15) UPA 7.5 mg (n=16) PBO (n=19) UPA 15 mg (n=18) PBO (n=19) UPA 30 mg (n=19)
Mean Percent Improvement from Baseline in EASI Scorea 34% 97%*** 9% 48%* 12% 44%* 22% 69%**
Mean Percent Improvement from Baseline in Pruritus/Itch Numerical
Rating Scaleb
-6% 94%*** -6% 53%** 3% 44%** -13% 61%***
*p<0.05, **p<0.01, ***p<0.001aEczema Area and Severity Index (EASI) score is a tool used to measure the extent (area) and severity of atopic dermatitis

bItch was rated from 0 (no itch) to 10 (worst imaginable itch)

In this study, no new safety signals were detected.1 There were 2 serious adverse events in the placebo group re-randomized to receive upadacitinib 30 mg, including one serious infection and one case of non-melanoma skin cancer.1 No cardiovascular events (adjudicated), malignancies other than non-melanoma skin cancer, deep vein thrombosis (DVT) or pulmonary embolism (PE) occurred through week 32 in the Phase 2b study.1

Patient-reported Outcomes at Week 16: Itch, Skin Pain and Impact on Sleep Due to Atopic Dermatitis2

Results from an additional analysis in a subset of patients through week 16 showed that patients treated with upadacitinib had improvements on patient-reported outcomes covering itch and the impact of atopic dermatitis on sleep.2 In the study, patients (n=14/6/9 subjects receiving UPA 7.5/15/30 mg and n+15 receiving placebo) completed a symptom and impact questionnaire daily, which included three items to assess itch and skin pain (itch during sleep, itch while awake, skin pain) and three items to assess impact on sleep (difficulty falling asleep, sleep impact, bother from waking up at night).2

Improvements on all measures were observed as early as week 2 for all upadacitinib dose groups compared to placebo.2 At week 16, only the upadacitinib 30 mg group showed improvements on all measures except skin pain.2

Patient-reported outcomesare an important component of understanding how patients perceive the physical, psychological and social burden of their disease.6 Using patient-reported outcomes data to assess the impact of the disease allows patients to take an active role in their treatment journey providing valuable insight to their healthcare teams.

About the Phase 2b Upadacitinib Study1

Interim results were reported from an ongoing, 88 week dose-ranging, randomized, double-blind, parallel-group, placebo-controlled multicenter Phase 2b study designed to evaluate the safety and efficacy of upadacitinib in adult patients with moderate to severe atopic dermatitis not adequately controlled by topical treatments, or for whom topical treatments were not medically advisable. In Period 1 (16 weeks), subjects were randomized in a 1:1:1:1 ratio to one of four treatment groups (three upadacitinib dosing groups, 30/15/7.5 mg once-daily, and one placebo group). In Period 2 (72 weeks), each upadacitinib group was re-randomized in a 1:1 ratio to continue the Period 1 dose or placebo (withdrawal). Patients randomized to placebo in Period 1 were re-randomized at week 16 to either upadacitinib 30 mg once-daily or placebo. After four weeks of re-randomization (week 20), rescue therapy with upadacitinib 30 mg once-daily was provided after the first instance of a less than EASI 50 response. The primary endpoint of the study was the mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at 16 weeks. Secondary endpoints included the proportion of patients achieving EASI 90, EASI 75, Investigator Global Assessment (IGA) of 0 or 1 and percent change in pruritus/itch numerical rating scale (NRS). More information on this trial can be found at www.clinicaltrials.gov (NCT02925117).

About Upadacitinib

Discovered and developed by AbbVie, upadacitinib is a once-daily oral, small molecule JAK1-selective inhibitor being developed for moderate to severe atopic dermatitis and other immune-mediated diseases.1-3

Upadacitinib is an investigational oral agent and is not approved by regulatory authorities. Safety and efficacy have not been established.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

###

UK Media Contacts

Matthew Worrall, Senior Brand Communications and Patient Relations Manager, AbbVie

matthew.worrall@abbvie.com

+44 (0) 7464 652 626

References

  • 1.Guttman-Yassky, E et al. ePoster #P0236. 27th European Academy of Dermatology and Venerology (EADV) Congress. September 2018.
  • 2.Silverberg, J et al. Presentation#FC04.03. 27th European Academy of Dermatology and Venerology (EADV) Congress. September 2018.
  • 3.Voss, J, et al. Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects. [abstract]. Arthritis Rheum 2013;65 Suppl 10 :2374. DOI: 10.1002/art.2013.65.issue-s10.
  • 4.Nutten S, Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl 1):8-16 2. Accessed on September 6, 2018.
  • 5.Wei, W, et al. Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey. Am J Clin Dermatol. 2017; 18(6): 825–835.
  • 6.Deshpande, PR et al. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011 Oct-Dec; 2(4): 137–144.

Date of preparation: September 2018

Job code: AXUPC181173

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Read more »

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

Press Releases   •   Sep 13, 2018 11:34 BST

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis

  • Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA (ustekinumab) after 16 weeks and at one year (52 weeks) compared to ustekinumab1
  • In the IMMvent study, significantly more patients treated with risankizumab self-reported a Dermatology Life Quality Index score of 0 or 1 compared with HUMIRA® (adalimumab)-treated patients after 16 weeks2
  • Risankizumab-treated patients reported significant improvements in measures of health-related quality of life, mental health and work productivity1,2

Maidenhead, UK, 13th September, 2018– AbbVie, a research-based global biopharmaceutical company, today announced new patient-reported outcomes data from three pivotal Phase 3 trials evaluating risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in adult patients with moderate to severe plaque psoriasis. Across all three trials, patients reported significant improvements in health-related quality of life, mental health and work productivity measures when treated with risankizumab.1,2Data from these studies will be presented at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris. Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.

At week 16, significantly more risankizumab-treated patients reported a psoriasis symptom scale (PSS) score of 0, indicating they were symptom-free based on a score assessing pain, redness and itchiness, compared with STELARA (ustekinumab) and placebo in ultIMMa-1 and ultIMMa-2.1 Significantly more patients treated with risankizumab continued to report a PSS score of 0 at one year (52 weeks) compared to ustekinumab.1 In IMMvent, significantly more patients treated with risankizumab achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating psoriasis no longer had impact on their life quality, compared to HUMIRA® (adalimumab) at week 16.2 Risankizumab-treated patients maintained reported outcomes at week 44 in IMMvent.2 Improvements in hospital anxiety and depression scales (HADS) and work limitation questionnaire (WLQ), a measure of work productivity, were also reported.1,2

Safety results from all three Phase 3 trials have been previously reported.3,4

“Patients treated with risankizumab reported significant improvements in severity of psoriasis symptoms and measures of quality of lifecompared to current standards of care, as consistently demonstrated by the results of all three Phase 3 pivotal trials,” said Marek Honczarenko, M.D., Ph.D., vice president, global immunology development, AbbVie. “Patients with psoriasis are seeking new treatment options that help them not only to achieve and maintain clear skin, but may also improve their quality of life. These results add to the growing body of evidence demonstrating that risankizumab has the potential to be an important additional treatment option for patients with plaque psoriasis.”

Patient-reported outcomesare an important component of understanding how patients perceive the physical, psychological and social impact of their disease.5 Using patient-reported outcomes to assess disease activity helps patients to take an active role in their treatment journey, providing valuable insights to their healthcare team.5

“Psoriasis can impact many aspects of a person’s life, both physically and psychologically,” said Prof. Matthias Augustin, Director, Institute and German Center for Health Services Research in Dermatology and Nursing IVDP, University Medical Center Hamburg. “Improvements in quality of life reported by patients as early as week 16 and up to one year show risankizumab’s potential to significantly reduce the burden of psoriasis on daily life and adds to our knowledge about its clinical efficacy in psoriasis patients.”

Psoriasis Symptom Scale (PSS)1

  • In pooled analyses from ultIMMa-1 and ultIMMa-2, significantly more patients treated with risankizumab (n=598) reported a PSS of 0 compared to placebo (n=200) and ustekinumab (n=199), indicating they were symptom-free based on pain, redness, itchiness and burning. At week 16, 30 percent of patients receiving risankizumab had a PSS score of 0, compared with 15 and 1 percent of patients receiving ustekinumab and placebo, respectively (p<0.001). At one year, 56 percent of risankizumab-treated patients reported being symptom free (PSS = 0), compared with 30 percent of patients receiving ustekinumab (p<0.001).

Dermatology Life Quality Index (DLQI)2

  • Dermatology Life Quality Index is a measure of a patient's health-related quality of life, ranging from 0 to 30, with lower scores indicating the disease has less impact on life quality. In IMMvent, risankizumab (n=301) was associated with significantly greater improvement in DLQI score from baseline than adalimumab (n=304) at week 16 (with an 11.5 point reduction in DLQI score versus 9.7 points, p<0.001). Significantly more patients treated with risankizumab achieved a DLQI score of 0 or 1 (66 percent) compared to adalimumab (49 percent) at week 16 (p<0.001). At week 44 patients maintained benefit, with 66 percent of risankizumab-treated patients achieving a DLQI score of 0 or 1 and the percentage of adalimumab-treated patients was 57 percent.

Hospital Anxiety and Depression Scale (HADS)1

  • Hospital Anxiety and Depression Scale is a self-assessment scale designed to measure depression, anxiety and emotional distress, with scores ranging from 0 to 21 (increasing in severity). In pooled analyses from ultIMMa-1 and ultIMMa-2, risankizumab-treated patients reported significantly greater improvements from baseline on the HADS anxiety and depression scales (scores reduced by 3 points for anxiety and 2.7 points for depression, respectively) compared to ustekinumab (scores reduced by 2.2 points for anxiety and 2 points for depression, respectively) and placebo (scores reduced by 0.8 points for anxiety and 0.2 points for depression, respectively) at week 16 (p<0.01).

Work Limitation Questionnaire (WLQ)2

  • The Work Limitation Questionnaire measures the degree to which health problems interfere with aspects of job performance and the productivity impact of these work limitations. Work Limitation Questionnairescores range from 0 to 100, with lower scores indicating less amount of time that health interferes with job demands and productivity. In IMMvent, patients receiving risankizumab showed a significantly larger improvement in WLQ total productivity loss from baseline compared to those receiving adalimumab at week 16 (score reduced by 2.8 percent versus 1.9 percent, p<0.05). The benefits gained were maintained at week 44, with risankizumab-treated patients WLQ productivity loss score reduced by 3.3 percent and adalimumab-treated patients score reduced by 2.6 percent, based on a mean reduction from baseline. Work Limitation Questionnaire subscales were also presented.

About the Phase 3 ultIMMa-1 and ultIMMa-2 studies3

ultIMMa-1 and ultIMMa-2 are replicate Phase 3, randomized, double-blind, double-dummy, placebo- and active-controlled studies designed to evaluate the safety and efficacy of risankizumab compared to placebo or ustekinumab in adult patients with moderate to severe chronic plaque psoriasis. Risankizumab (150 mg) was given as a subcutaneous injection at week 0, 4, 16, 28, 40. Ustekinumab 45 mg or 90 mg, based on screening weight, was delivered as a subcutaneous injection at week 0, 4, 16, 28, 40. The active comparator used for these studies was sourced from the European Union. The co-primary endpoints were achievement of at least a 90 percent improvement in the PASI score (PASI 90) at week 16 and achievement of a sPGA score of clear or almost clear (0/1) at week 16 compared to placebo. Key secondary endpoints included PASI 90 and sPGA score of clear or almost clear (0/1) compared to ustekinumab at Week 16 and achievement of PASI 90 and PASI 100 at week 52 compared to ustekinumab. These Phase 3 studies have been conducted in cooperation between AbbVie and Boehringer Ingelheim. More information on these trials can be found at www.clinicaltrials.gov (ultIMMa-1: NCT02684370; ultIMMa-2: NCT02684357).

About the Phase 3 IMMvent study4

The IMMvent study is a Phase 3 randomized, double-blind, double-dummy, active-controlled study designed to evaluate the safety and efficacy of risankizumab compared to adalimumab in adult patients with moderate to severe chronic plaque psoriasis. In the first phase patients were randomized 1:1 to either risankizumab (150 mg), given as a subcutaneous injection at baseline, 4 weeks later and every 12 weeks thereafter or adalimumab, given as a subcutaneous injection, with an initial dose of 80 mg followed by 40 mg every other week starting one week after the initial dose. The co-primary endpoints were achievement of at least a 90 percent improvement in the PASI score (PASI 90) at week 16 and achievement of a sPGA score of clear or almost clear (0/1) at week 16.

Patients originally randomized to risankizumab received it throughout the study. Those originally randomized to adalimumab followed a treatment course based on week 16 response: those with less than PASI 50 at week 16 switched to risankizumab; those with PASI 90 continued adalimumab; and those with a PASI 50 but less than PASI 90 response were re-randomized to switch to risankizumab or continue adalimumab. For this phase, PASI 90 at week 44 was the primary endpoint for those patients re-randomized at week 16. PASI 100 at week 44 was the ranked secondary endpoint. This Phase 3 study has been conducted in cooperation between AbbVie and Boehringer Ingelheim. More information on this trial can be found at www.clinicaltrials.gov (NCT02694523).

About the Risankizumab Phase 3 Psoriasis Program3,4,6

The global risankizumab Phase 3 psoriasis program evaluates more than 2,000 patients with moderate to severe plaque psoriasis in four pivotal studies. The studies include assessments of efficacy, safety and tolerability of risankizumab. Key measures of efficacy include measures of disease activity and skin clearance, including PASI 90, PASI 100 and sPGA 0/1, as well as long-term clinical outcomes. More information on this program can be found at www.clinicaltrials.gov (NCT02672852, NCT02694523, NCT02684370, NCT02684357).

About Risankizumab

Risankizumab is an investigational compound that is designed to selectively block IL-23 by binding to its p19 subunit. IL-23, a key cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.7

Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading future development and commercialization of risankizumab globally. Risankizumab is not approved by regulatory authorities. Safety and efficacy have not been established.

###

UK Media Contacts

Matthew Worrall, Senior Brand Communications and Patient Relations Manager, AbbVie

matthew.worrall@abbvie.com

+44 (0) 7464 652 626

References:

1.Augustin, M., et al. ePoster #1996. 27th European Academy of Dermatology and Venereology (EADV) Congress. September 2018.

2.Crowley, J., et al. ePoster #P1947. 27th European Academy of Dermatology and Venereology (EADV) Congress. September 2018.

3.Gordon K, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet. 2018 Aug 25;392(10148):650-661.

4.Reich, K., et al. ePoster #P1813. 27th European Academy of Dermatology and Venereology (EADV) Congress. September 2018.

5.Deshpande, P.R. et al. Patient-reported outcomes: A new era in clinical research. Perspect Clin Res. 2011 Oct-Dec; 2(4): 137–144.

6.Blauvet, A., et al. Presentation # FC29. Psoriasis Gene to Clinic – 8th International Congress. October 2017.

7.Duvallet E, Sererano L, Assier E, et. al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011 Nov;43(7):503-11.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Read more »

AbbVie UK publishes 2017 transparency data

Press Releases   •   Jun 29, 2018 12:25 BST

AbbVie annual transparency publication of transfer of value data to healthcare professionals, healthcare organisations and patient organisation goes live 29 June 2018.

AbbVie UK Launches Third Annual ‘Big Ideas for Better Health’ Awards

Press Releases   •   May 22, 2018 05:00 BST

-Awards celebrate forward-thinking individuals and teams who are championing innovation and supporting the NHS to become more resilient and sustainable -Independent judging panel led by Patients Association -Winning teams receive £3000 bursary to spread their work

AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis

Press Releases   •   May 02, 2018 10:10 BST

• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing

New Presentation, HUMIRA® (adalimumab) 20 mg/0.2 mL for Injection in Pre-filled Syringe (PFS) Launched for Paediatric Patients, together with the Introduction of Fixed Weight Dosing

Press Releases   •   Mar 29, 2018 16:06 BST

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications (paediatric polyarticular juvenile idiopathic arthritis, paediatric enthesitis related arthritis, paediatric Crohn’s disease, paediatric plaque psoriasis and paediatric Uveitis).

The formulation contains the same active ingredient, adalimumab, and the efficacy and safety profile remains unchanged. In 2016 AbbVie introducted a citrate free adalimumab 100 mg/mL formulation and launched Humira 40 mg/0.4 mL. The HUMIRA 20 mg/0.2 mL will be available to the UK Market at the beginning of quarter two (April 2018).

"The launch of the HUMIRA 20 mg/0.2 mL presentation underscores our ongoing dedication to improving the patient experience through research and enhancements,” said Alice Butler, Medical Director, AbbVie. “We remain committed to innovation in immunology in order to improve upon the therapeutic experience of patients and physicians.”

Professor Ramanan, Consultant Paediatric Rheumatologist, Bristol Royal Hospital for Children & Royal National Hospital for Rheumatic Diseases, said: “The introduction of HUMIRA 20 mg/0.2 mL is welcome news for paediatric patients, that will provide significant reduction in pain on administration for paediatric patients”.

Kit Tranter, Lead Paediatric Rheumatology Nurse Specialist at Jenny Lind Children's Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust said: “This will be met positively by the Paediatric Nursing community as the implications for empowering young people and their families, improving quality of life by reducing the technical nature of administering paediatric doses, reducing waste whilst maintaining good control of long term conditions shouldn’t be underestimated. I’m delighted that the specific needs of the paediatric rheumatology patient group have been recognised and acted upon to improve the overall experience”.

The paediatric dosing has been simplified. Instead of using body surface area as a calculation of dose required, the calculation is based on age and weight and will utlilise the newly available HUMIRA 20 mg/0.2mL and current HUMIRA 40 mg/0.4 mL.

-ENDS-


Notes to editors

About HUMIRA® (adalimumab)

For further information, and recommended dosing of HUMIRA for each paediatric indication, please see the Summary of Product Characteristics: http://www.medicines.org.uk/emc.

Important EU Safety Information

HUMIRA is contraindicated in patients with active tuberculosis or other severe infections such as sepsis, and opportunistic infections and in patients with moderate to severe heart failure (NYHA class III/IV). It is also contraindicated in patients hypersensitive to the active substance or to any of the excipients. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with HUMIRA. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache and musculoskeletal pain.

###

UK Media Contacts

Cheryl Pitcher Email: cheryl.pitcher@abbvie.com

Tel: 07500 786 466

References:

1) HUMIRA [Summary of Product Characteristics]. AbbVie Ltd.; Available at: https://www.medicines.org.uk/emc/search?q=humira. Accessed 28th March 2018.

Date of preparation: March 2018

Zinc reference no: AXHUM180208

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications.

Read more »

AbbVie’s Duodopa® (levodopa-carbidopa intestinal gel) recommended for use within NHS Wales

Press Releases   •   Mar 27, 2018 09:46 BST

MAIDENHEAD, UK, 26 March 2018 – AbbVie, a global research and development-based biopharmaceutical company, today announced that its advanced Parkinson’s therapy, Duodopa®, has been recommended for use within NHS Wales, following an assessment by the All Wales Medicines Strategy Group (AWMSG)1. Levodopa-carbidopa intestinal gel is recommended for the treatment of advanced levodopa-responsive Parkinson’s with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results, and when patients are not eligible for deep brain stimulation.

AbbVie UK General Manager, Jerome Bouyer, said: “We welcome the news that the AWMSG has recommended Duodopa® for this population of patients with advanced Parkinson’s. NHS Health Boards in Wales must now ensure that the therapy is made available within the statutory two months of the publication of the final guidance, as mandated by the Wales new treatment fund. A small number of patients rely on Duodopa® so it’s critical that they get swift access to the therapy that they need.”

The projected 2018 prevalence of Parkinson’s in Wales is 7,6922 .Parkinson’s is a condition that leads to a loss of the chemical dopamine in the brain, which controls movement and balance.3Levodopa-carbidopa intestinal gel is administered directly through the intestine, bypassing the stomach, and may be prescribed for some people with Parkinson’s who have tried other combinations of medicines but do not have satisfactory control of their motor symptoms (movement and balance).4

Steve Ford, Chief Executive, Parkinson’s UK commented: “This is good news for people living with advanced Parkinson’s in Wales, some of whom may have no other viable treatment option available to them.”

Levodopa-carbidopa intestinal gel (LCIG) contains the medicines levodopa and carbidopa. LCIG is delivered continuously and directly into the intestine via a tube that passes through the abdominal wall. LCIG is delivered via a pump that is carried by the patient during the day. If medically justified, LCIG may also be administered during the night.4

Levodopa-carbidopa intestinal gel is not suitable for all patients and therefore the SmPC should be referred to for full details and side effects. Please visit https://www.medicines.org.uk/emc/product/6231.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AbbVie UK Ltd. Please contact ukadverseevents@abbvie.com. With biological medicines, healthcare professionals should report adverse reactions by brand name and batch number.

-ENDS-

Notes to editors

About Parkinson’s

  • The projected 2018 prevalence of Parkinson’s in Wales is 7,6922 .Parkinson’s is a condition in which part of the brain becomes progressively damaged over many years. Itis caused by a loss of nerve cells in the part of the brain responsible for producing a chemical called dopamine. Dopamine plays a vital role in regulating the movement of the body and a reduction in dopamine is responsible for many of the symptoms of Parkinson's disease.3
  • The main symptoms of Parkinson's are tremor, rigidity and slowness of movement, these are often called motor symptoms.As well as affecting movement, people with Parkinson's can find that other issues, such as tiredness, pain, depression and constipation, can have an impact on their day-to-day lives. The symptoms someone has and how quickly the condition develops will differ from one person to the next. Most people with Parkinson’s start to develop symptoms when they’re over 50, although around 1 in 20 people with the condition first experience symptoms when they’re under 40.3
  • The term 'advanced Parkinson's' usually refers to a time when symptoms are more complex and have more of an effect on day-to-day life.People at this stage may find that they are no longer able to do tasks such as washing and dressing without help from someone else, perhaps a carer. Around 10% per cent of people with Parkinson’s progress toadvanced stage.5

UK media contacts

Sarah Beck

sarah.beck@abbvie.com

+44 (0)7818 428111

References

1 AWMSG Final Appraisal Recommendation, ref 3397 http://www.awmsg.org/awmsgonline/app/appraisalinfo/3397, (last accessed, March 2018)

2 Parkinson’s UK, The Incidence and Prevalence of Parkinson’s in the UK; Results from the Clinical Practice Research Datalink Summary report http://www.parkinsons.org.uk/sites/default/files/2018-01/CS2960%20Incidence%20and%20prevalence%20report%20branding%20summary%20report.pdf(last accessed, March 2018)

3 NHS Choices. Parkinson’s Disease http://www.nhs.uk/Conditions/Parkinsons-disease/Pages/Introduction.aspx (last accessed, March 2018)

4 Electronic Medicines Compendium, Duodopa Summary of Product Characteristics

https://www.medicines.org.uk/emc/product/6231 (last accessed, March 2018)

5 Worth P. When the going gets tough: how to select patients with Parkinson’s disease for advanced therapies, Pract. Neurol. 2013;0:1-13

About AbbVie

AbbVie is a global, research and development biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

All Wales Medicines Strategy Group (AWMSG) recommends levodopa-carbidopa intestinal gel as an option for the treatment of advanced Parkinson’s in patients not eligible for deep brain stimulation

Read more »

NEARLY TWO THIRDS PUT OFF SEEING DOCTORS DUE TO DIAGNOSIS FEARS – NEW QUIZ LAUNCHED TODAY TO UNDERSTAND WHY

Press Releases   •   Feb 15, 2018 00:01 GMT

New ‘Crush Your FOFO’ quiz will help experts and the public better understand FOFO which is preventing people from seeking medical advice

NICE recommends AbbVie’s HUMIRA® (adalimumab) for treatment of non-infectious uveitis

Press Releases   •   Feb 12, 2018 13:42 GMT

  • NICE publishes guidance recommending AbbVie’s HUMIRA® (adalimumab) as an option for treating eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids1
  • Non-infectious uveitis can lead to reduced vision or vision loss and is the third-leading cause of preventable blindness worldwide2,3
  • Adalimumab is the first and only biologic medicine licensed for adult patients with certain types of non-infectious uveitis

MAIDENHEAD, UK, 26 July 2017 – AbbVie, a global biopharmaceutical company, today announced that the National Institute for Health and Care Excellence (NICE) has recommended HUMIRA® (adalimumab) as a clinically and cost effective treatment option for eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids1.

Uveitis is an uncommon group of inflammatory eye conditions which can be caused either by infection or abnormal activation of the immune system in the uvea, the middle part of the eye4,5. Non-infectious uveitis can lead to reduced vision or vision loss and is the third-leading cause of preventable blindness worldwide2,3. It can affect both children and adults and is more common in people with an existing inflammatory or autoimmune condition5.

This NICE Technology Appraisal Guidance (TAG), which also provides recommendations on the use of dexamethasone, follows the publication of the ‘Interim Clinical Commissioning Policy Statement: Adalimumab for Severe Refractory Uveitis’ in March 20176. It means that, for eligible patients, routine treatment is not limited to steroids and/or immunosuppressants. Treatment with steroids can be associated with a number of complications, therefore patients who have had an inadequate response to or who are intolerant to steroids and/or immunosuppressants may require another treatment option to control the inflammation in the eye5,7. Adalimumab is the first and only biologic medicine licensed for adult patients with certain types of non-infectious uveitis (intermediate, posterior and pan-uveitis).

Annie Folkard, Co-Founder, Birdshot Uveitis Society said, “We are delighted that there is now another treatment option for those adults with severe uveitis who have not responded to other forms of treatment and who are at greatest risk of going blind. The effects of uveitis can be devastating. Not only can it make everyday tasks very difficult, but uncontrolled uveitis can also lead to irreversible deterioration of vision and ultimately blindness.”

Jessica Hall, RNIB Eye Health Policy Officer, said: “We very much welcome NICE’s recommendations as we finally have a routinely available treatment option, which has been shown to be safe and effective for those adults most at risk of sight loss.”

Mr Fahd Quhill, Consultant Ophthalmologist, Royal Hallamshire Hospital said, “Uveitis can be difficult to diagnose and treat, but due to its potentially life-long impact and the risk of complications it’s essential that the condition is treated effectively and inflammation is controlled. This new NICE guidance represents significant progress for those uveitis patients most at risk of going blind.”

This NICE TAG recommends adalimumab as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, only if there is: active disease; inadequate response or intolerance to immunosuppressants; systemic disease or both eyes are affected; and worsening vision with a high risk of blindness1.

When NICE recommends a treatment ‘as an option’, the NHS is required to comply with the recommendations and make it available for eligible patients in England and Wales within 3 months of the guidance being published1.

The NICE TAG recommendation for adalimumab is based on efficacy and safety data from two randomised controlled trials, VISUAL-I and VISUAL-II. The studies demonstrated that adult patients with either active or controlled non-infectious intermediate, posterior and panuveitis treated with adalimumab had a significantly lower risk for uveitic flare or decrease in visual acuity, compared to placebo8,9.

-ENDS-

Notes to editors

About adalimumab

For further information, please see the Summary of Product Characteristics:

http://www.medicines.org.uk/emc

About RNIB

Every 15 minutes, someone in the UK begins to lose their sight. We are the Royal National Institute of Blind People (RNIB) and we're here for everyone affected by sight loss - that's almost 2 million people in the UK. If you, or someone you know, has a sight problem, RNIB can help. Call the RNIB Helpline on 0303 123 9999 or visit www.rnib.org.uk

References:

1 National Institute for Health and Care Excellence. Adalimumab and dexamethasone for treating non-infectious uveitis Technology appraisal guidance [TA460]. July 2017. Available at: www.nice.org.uk/guidance/ta460 [Last accessed: July 2017].

2 Durrani OM, et al. Degree, duration, and causes of visual loss in uveitis. British Journal of Ophthalmology 2004;88:1159-1162.

3 Siddique SS, et al. Glaucoma and Uveitis. Survey of Ophthalmology 2013;58(1-10).

4 Jabs DA, et al. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. American Journal of Ophthalmology 2005;140(3):509-516.

5 Guly CM and Forrester JV. Investigation and Management of Uveitis. BMJ 2010;341:821-826.

6 NHS England, Specialised Services Clinical Reference Group for Specialised Ear and Ophthalmology CRG, ‘Interim Clinical Commissioning Policy Statement: Adalimumab with Severe Refractory Uveitis’. Available at: https://www.england.nhs.uk/wp-content/uploads/2017/03/clin-com-pol-statment-170010ps.pdf. [Last accessed: July 2017].

7 McCluskey PJ, et al. Management of Chronic Uveitis. BMJ 2000;320:555-558.

8 Jaffe GJ, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med 2016;375(10):932-43.

9 Nguyen QD, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet 2016;388:1183-1192.

 AXHUR171031

Date of prep: July 2017

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

NICE publishes guidance recommending AbbVie’s HUMIRA® (adalimumab) as an option for treating eligible adults with certain types of non-infectious uveitis who have had an inadequate response to corticosteroids

Read more »

Response To Announcement Of NHS England’s Plans To Be First In The World To Eliminate Hepatitis C

Press Releases   •   Jan 26, 2018 08:46 GMT

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term. This follows the lead of industry’s multi-billion investment in the development of curative treatments for patients, and also our work with partners to diagnose and find those that remain undiagnosed, estimated to be half of the 160,000 affected by hepatitis C in England. 

Since curative treatments became available in 2015, AbbVie has been seeking ways of making cure sustainable for the NHS and we continue to invest in advancing patient pathways and services, through collaborating with multilateral groups including patient organisations, drug & alcohol services and prisons. Sustained, long-term commitment to the funding of these elements is just as critical as the procurement of medicines if the NHS in England is to realise its ambitious vision to eliminate hepatitis C five years earlier than the World Health Organization’s 2030 goal; a goal which we support. 

We have been working closely and collaboratively with NHS England to build towards the elimination strategy and will continue to do so in order to find sustainable approaches to funding and increased access to treatments and services for all those affected by hepatitis C.

AXHCV180095 Date of preparation: January 2018

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

MAIDENHEAD, UK, January 28, 2017 – We welcome NHS England’s announcement of their plans towards the elimination of hepatitis C in England and we are encouraged to see a commitment being made for the long-term.

Read more »

Contacts 9 contacts

  • Press Contact
  • Director of Communications & Patient Relations
  • gwxaenepanss.wzdhijuteeb@aaubbwrviype.hycobzmcv
  • 07876 391 429

  • Press Contact
  • Head of Patient Relations & Brand Communication
  • phsnilczipjrpahh.mafankrnifdngco@axabbewviske.mhcovamfj
  • 07818 428 081

  • Press Contact
  • Senior Corporate Communications Manager
  • Policy comms; Transparency; Corporate projects
  • mavpttkrheixw.efwoofrrizalmql@amabafbvszieez.cohomlb
  • 07464 652 626

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Oncology & Dermatology
  • dazunijrelutlemq.sugmivythvb@avpbbxvviqge.accovumkf
  • 07825 078 734

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Oncology
  • joaeantsnahq.jyponoaesdn@atubbggviqbe.ijcowkmro
  • 07795 590 344

  • Press Contact
  • Corporate Communications Specialist
  • Digital communication
  • flboorkvenjqcemg.csehidgnnsc@avmbbjavidhe.licobrmym
  • 07990 089 023

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Pan-Immunology & AbbvieCare
  • chzqerohylmh.pqxitbachxzerwj@avvbbtwvivje.igcoxmmsh
  • 07500 786 466

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Immunology - Gastroenterology & Rheumatology
  • naqptaxylixve.qibetznnqhetlgt@rdabaybvprievc.ccbomjf
  • 07818 428 074

  • Press Contact
  • Senior Communications and Patient Relations Manager
  • Hepatitis C; Paediatrics; Neurology
  • sajgraqkh.vbbehackyf@atqbbnpvibme.nrcoslmsc
  • 07818 428 111

About AbbVie UK

We're a company that takes on the toughest health challenges.

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.

Address

  • AbbVie UK
  • AbbVie House, Vanwall Business Park, Vanwall Road
  • SL6 4UB Maidenhead
  • United Kingdom